Treatment of Cutaneous Lupus
Cutaneous lupus erythematosus (CLE) is an autoimmune inflammatory skin disease seen in patients with or without systemic lupus erythematosus. The management of CLE includes treatment and prevention of lesions as well as routine assessment for systemic disease. Treatment options include topical and systemic therapies. Topical therapies include corticosteroids and calcineurin inhibitors. Systemic therapies generally fall under one of three categories: antimalarials, immunomodulators (eg, dapsone and thalidomide), and immunosuppressives (eg, methotrexate and mycophenolate). Evidence for the treatment of CLE has been limited by few prospective studies and the lack of a validated outcome measure (until recently). There is good evidence to support the use of topical steroids and calcineurin inhibitors, although most of these trials have not used placebo or vehicle controls. There have been no randomized, placebo-controlled trials evaluating systemic therapies in the treatment of CLE.
KeywordsCutaneous lupus erythematosus Treatment Topical steroids Topical calcineurin inhibitors Antimalarials Immunomodulators Immunosuppressives Cutaneous lupus erythematosus disease area and severity index CLASI
Papers of particular interest, published recently, have been highlighted as: ••Of major importance
- 4.•• Fett N, Werth VP (2011, In press) Treatment of cutaneous lupus erythematosus. In: Maibach H, editor. Evidence Based Dermatology. 2nd ed. This is a thorough, evidence-based review of treatments used in CLE. It addresses treatment efficacy by focusing on level of evidence as well as study design and outcome measures. It includes a focused summary section on the level of evidence for different treatments used. Google Scholar
- 5.•• Kuhn A, Ruland V, Bonsmann G (2010) Cutaneous lupus erythematosus: update of therapeutic options part I and part II. J Am Acad Dermatol. This is a comprehensive and detailed two-part review of treatment options, including details on CLE subtypes and medication dosing used in studies. It provides a diagrammatic treatment algorithm. Google Scholar
- 28.Chang AY, Piette E, Foering KP, Okawa J, Werth VP. Response to antimalarials in cutaneous lupus erythematosus. J Invest Dermatol (abstract). 2011;131 Suppl 1:S80.Google Scholar
- 39.Alsanafi S, Kovarik C, Mermelstein AL, Werth VP. Rituximab in the treatment of bullous systemic lupus erythematosus. J Clin Rheumatol. 2011;17 3:142–4.Google Scholar